Director, Quantitative Pharmacology & Pharmacometrics - Oncology

Merck Merck · Pharma · NJ

Director level role in Quantitative Pharmacology & Pharmacometrics for Oncology at Merck, focusing on drug development from post-PCC to registration. Responsibilities include leading quantitative analyses, developing PK/PD and disease progression models, and ensuring regulatory compliance. Requires a Ph.D. with significant pharmaceutical drug development experience and proficiency in modeling software.

What you'd actually do

  1. Serving as an expert representative for QP2 -IO on Oncology development teams.
  2. Framing critical questions and strategy for optimizing model-based analyses on programs.
  3. Developing and executing model-based analyses including translational PK/PD approaches, population pharmacokinetic models, exposure-response models, clinical trial design simulation, disease progression models, quantitative systems pharmacology (QSP) modeling, and comparator modeling.
  4. Strategizing and executing modeling of tumor size and survival.
  5. Maintaining a comprehensive understanding of global regulatory expectations for small molecules and biologics in Oncology, authoring regulatory documents (investigational new drugs/INDs, clinical study reports (CSRs), clinical trial applications (CTDs), and representing QP2-IO at regulatory meetings.

Skills

Required

  • Clinical Pharmacology
  • Communication
  • Data Modeling
  • Data Visualization
  • Drug Development
  • Modeling Software
  • Pharmacology
  • Pharmacometrics
  • Program Leadership
  • Stakeholder Relationship Management
  • R
  • NONMEM
  • MATLAB
  • Monolix

Nice to have

  • Antibody Drug Conjugates (ADC)
  • Biologics
  • Oncology
  • Small Molecule Drugs
  • T Cell Engagers
  • Quantitative Systems Pharmacology (QSP)

What the JD emphasized

  • Ph.D. with at least seven years of pharmaceutical drug development experience
  • Masters or PharmD, with at least nine years of experience
  • Demonstrated impact with applications of pharmacometrics methods.
  • Experience in IND, NDA and other submissions to global regulatory agencies.
  • An exemplary record of increasing responsibility, independence, and demonstrated impact in driving drug development decisions through application of model-based approaches.